Webinars and Sponsored Roundtables — Register Now

Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.

Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

Product Spotlight

Roche Diagnostics

cobas pure integrated solutions 

Company

Roche Diagnostics

Name of instrument

cobas pure integrated solutions 

Contact

Brianna Frederick  

Email

brianna.frederick@roche.com

City, State

Indianapolis, IN

Phone

800-428-5074  

Website

https://diagnostics.roche.com/us/en/home.html

Type of instrument

combination chemistry/immunoassay

Operational type/Model type

random access, continuous random access/floor standing

List price/First year sold in U.S.

—/2022

Targeted hospital bed size/Targeted test volume

< 200/daily: 410–2,054; monthly: 12,500–62,500; annual: 150,000–750,000

Company manufactures instrument

no (manufactured by Hitachi High-Technologies)

Other models in this family of analyzers

chem: cobas c 303; immuno: cobas c 402

No. of units in clinical use in U.S./Outside U.S. (countries)

< 1,000/> 1,000 (> 50 countries)

Dimensions (H × W × D)/Instrument footprint

5.8 × 8 × 2.6 ft./21 sq. ft.

Weight empty/Weight fully loaded

2,205 lbs./2,205 lbs.

No. of different measured assays onboard simultaneously

up to 73 (up to 73 can be run and calibrated at one time [chem: 42, immuno: 28, ISE: 3])

No. of user-definable (open chemistry) channels

10 (10 can be active simultaneously)

Test throughput per hour/Assay run time

870 (up to 300 photometric, 450 ISE tests in throughput)/chem: 4–10 min. (avg. 10 min.); immuno: 9–27 min. (avg. 18 min.)

No. of direct ion-selective electrode channels

3

Detection methods

photometry, potentiometry 

Stat time until completion/specimen throughput for ion-selective electrode

4.5 min. for ISE, 10 min. with CO2/ISE: 150 specimens per hr. 

Stat time until completion/specimen throughput for basic metabolic panel

10 min./—

Stat time until completion/specimen throughput for complete metabolic panel

10 min./—

Typical time delay from ordering stat test until aspiration of sample

< 1 min.

Fully automated microplate immunoassay system

no

Methodologies supported

electrochemiluminescence

Separation methodologies

magnetic particle

Stat time until completion of a ß-hCG test

~10 min. 

Stat time until completion of a cTn test

~10 min. 

• Typical time delay from test order to aspiration of sample

< 1 min.

Approximate No. of tests per reagent set/Reagent type

up to 3,300 (chem), 300 (immuno)/self-contained multiuse

Reagents refrigerated onboard/Reagents ready to use

yes (5°–15°C [chemistry], 6°–10°C [immunoassay])/yes

Reagent lot tracking/Reagent inventory

yes/yes

Reagent form/Reagents barcoded

liquid chemistry (open reagent system)/yes

Separate reagent pack for each specimen/for each test run

no/yes

Walkaway capability/Walkaway duration

yes/30–45 min. 

Design of sample-handling system

5-position rack

Uses washable cuvettes/Uses disposable cuvettes

yes/yes (can store up to 210 cuvettes)

Min.–max. sample volume that can be aspirated at one time 

1–60 µL

Min. reaction volume/Min. specimen volume/Min. dead volume

75 µL/1.5 µL (chemistry), 4 µL (immunoassay)/50 µL

Dedicated pediatric sample cup

yes (dead volume: 50 µL)

Primary tube sampling

yes

Accommodates most standard tube sizes/Accepts nonstandard tube sizes

yes/yes (11 × 102 mm [chem], 13 × 102 mm [immuno])

Pierces caps on primary tubes

no

Protects against probe collision

yes

Detects clots/liquid level/short sample

yes/yes/yes

Detection or quantitation for hemolysis, icterus, lipemia, clots

quantitation for hemolysis, icterus, lipemia; detection for clots

Dilutes patient samples onboard/Susceptibility to carryover

yes (can be programmed to perform dilutions prior to analysis)/< 1 part per million (chemistry), no carryover (immunoassay)

Automatic rerun capability

yes

Sample volume can be diluted to rerun out-of-linear-range high results

yes

Sample volume can be concentrated to rerun out-of-linear-range low results

yes

Autocalibration/Multipoint calibration supported

yes (calibrants are not stored onboard)/yes (recommended avg. frequency: once per lot [chem], up to 84 days per lot [immuno])

Typical calibration frequency for ISE/therapeutic drugs/drugs of abuse/general chemistries/immunoassays

once per lot/once per lot/once per lot/once per lot/up to 84 days per lot

Automatic programmable start/Automatic programmable shutdown

yes (6.5 min. avg. start-up time)/yes

Onboard real-time QC/Onboard software capability to review QC

yes/yes

Supports multiple QC lot numbers per analyte

yes

Waste management

direct to drain

Sample barcode-reading capability/Autodiscrimination

yes (Interleaved 2 of 5, Codabar, Code 39, Code 128)/yes

Lab can control analyzer from remote computer

yes

Instrument can diagnose its own malfunctions

yes (operator intervention required to order parts)

System malfunctions can be diagnosed via remote monitoring

yes

UPS backup power supply

yes

Data-management capability/LIS or EHR systems interfaced

onboard, optional add-on (Bio-Rad MAS)/SCC Soft Computer, Meditech, Oracle Health, Epic, Clinisys, more

LIS interface provided/Bidirectional interface capability

yes (included in instrument price)/yes (broadcast download and host query)

Modem servicing provided/Service engineer on-site response time

yes/—

Mean time between failures

— (displays error codes for troubleshooting)

Average scheduled maintenance time by lab personnel

daily: < 5 min.; weekly: 30 min.; monthly: 59 min.

Maintenance records kept onboard for user/vendor

yes/yes (both include audit trail of who replaced parts)

Maintenance training demonstration module onboard

yes

Training included with purchase/Avg. time for basic user training

yes (~2 training slots per module)/4–5 days (at both vendor and customer sites)

Advanced operator training/Extra charge for follow-up or advanced training

yes (at vendor site)/yes

Warranty provided/Cost of annual service contract (24 h/7 d)

yes (1 year)/contract dependent

Distinguishing features (supplied by company)

minimal operator intervention with automated maintenance, automated calibration, and continuous loading of reagents; maximizes reagent use; long onboard reagent (up to 6 months) and calibration stabilities; increases revenue through expanded testing services

More products
in this guide

DxC 500 AU Clinical Chemistry Analyzer
DxC 500i Clinical Analyzer
Pictus 500 (P500)
DS2 Elite Automated ELISA System
Stat Profile Prime Plus
VITROS XT 3400 Chemistry Systems
B⋅R⋅A⋅H⋅M⋅S KRYPTOR compact PLUS